

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5943384

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARC VAN DIJK	06/22/2016
EKATERINA V. BREOUS-NYSTROM	06/21/2016
VOLKER SEIBERT	06/20/2016
RECEIVING PARTY DATA	
Name:	4-ANTIBODY AG
Street Address:	HOCHBERGERSTRASSE 60C
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	CH-4057
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16284811
Application Number:	16384116
CORRESPONDENCE DATA	
Fax Number:	(857)300-4001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(857) 300-4000
Email:	leslie.roberts@lathropgpm.com, internalip@lathropgage.com
Correspondent Name:	LATHROP GPM LLP
Address Line 1:	28 STATE STREET
Address Line 2:	7TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	612044 AND 611500 -1 OF 5
NAME OF SUBMITTER:	ANDREW T. WILKINS
SIGNATURE:	/Andrew T. Wilkins/
DATE SIGNED:	02/03/2020
Total Attachments: 2	
source=611215- AGBW-132 - Executed Assignment - Inventors to 4Antibody#page1.tif	
source=611215- AGBW-132 - Executed Assignment - Inventors to 4Antibody#page2.tif	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Marc VAN DIJK, Ekaterina V. BREOUS-NYSTROM**, and **Volker SEIBERT** hereby sell and assign to **4-Antibody AG**, a corporation formed under the laws of Switzerland, whose mailing address is Hochbergerstrasse 60C, CH-4057 Basel, Switzerland (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **Anti-OX40 Antibodies and Methods of Use Thereof** for which application(s) have a filing date of May 6, 2016 (also known as United States Application No. 15/148,720, International Application No. PCT/US2016/031257, Argentina Application No. P 16 01 01301 and Taiwan Application No. 105114161), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate

assignments in connection with such application(s) as the Assignee may deem necessary or expedient.




The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.


The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: <u>June 22, 2016</u>	Signature of Inventor: <u></u> Marc VAN DIJK
Date: <u>June 21, 2016</u>	Signature of Inventor: <u></u> Ekaterina V. BREOUS-NYSTROM
Date: <u>June 20, 2016</u>	Signature of Inventor: <u></u> Volker SEIBERT

ACCEPTED AND AGREED TO BY ASSIGNEE, 4-Antibody AG:

Signature:  Date: 06 July 2016

Printed Name: Christine M. Klasan

Title: Director

2808733_1.DOCX